AXNX — Axonics Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
- $3.63bn
- $3.28bn
- $366.38m
U.S. RESEARCH ROUNDUP- Boeing, Cooper Companies, Northern Trust
Brief: Axonics® Announces First Patient Implants In Canada With New Recharge-Free Sacral Neuromodulation System
Brief: Axonics Inc Says It Expands Sacral Neuromodulation Intellectual Property Portfolio
U.S. STOCKS ON THE MOVE-Under Armour, Microchip Tech,
U.S. STOCKS ON THE MOVE-Moderna, Ford, Meta
U.S. STOCKS ON THE MOVE-Robinhood, Poseida, Arcutis
Axonics drops on pricing share offering
Brief: Axonics Announces Pricing Of Public Offering Of Common Stock
Brief: Axonics Announces Offering Of 1.75 Mln Shares
U.S. RESEARCH ROUNDUP-Alight, Stagwell, Transmedics Group
Brief: Axonics Q2 Revenue Up 50% To $69 Mln
Axonics Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Axonics® Files Pma Supplement With FDA For Fourth Generation Rechargeable Neurostimulator
Brief: Axonics® Reports First Quarter 2022 Financial Results
Axonics Inc reports results for the quarter ended in March - Earnings Summary
Axonics Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Axonics Inc Launches Direct To Consumer Television Advertising Campaign
Brief: Axonics Receives FDA Approval For Recharge-Free Sacral Neuromodulation System
Axonics Inc reports results for the quarter ended in December - Earnings Summary